Marina Chiara Garassino, MD

home / authors / marina-chiara-garassino-md

Articles

Dr Garassino on the Potential Use of a TROP2 Biomarker to Predict Outcomes With Dato-DXd in NSCLC

October 8th 2024

Marina Chiara Garassino, MD, discusses the predictive utility of a TROP2 computational pathway biomarker for outcomes with Dato-DXd in pretreated NSCLC.

A panel of 5 experts on lung cancer seated at a long table

Clinical Pearls and Future Perspectives in Advanced NSCLC

Benjamin P. Levy, MD;Solange Peters, MD, PhD;Joshua K. Sabari, MD;Edward B. Garon, MD, MS;Marina Chiara Garassino, MD

January 3rd 2024

The expert panel closes its discussion with advice for community physicians and discusses the future treatment landscape for advanced non–small cell lung cancer.

Antibody-Drug Conjugates in EGFR-Mutant NSCLC

Benjamin P. Levy, MD;Solange Peters, MD, PhD;Joshua K. Sabari, MD;Edward B. Garon, MD, MS;Marina Chiara Garassino, MD

December 27th 2023

The panel discusses the use of antibody-drug conjugates for patients with EGFR-mutant non–small cell lung cancer, with a focus on the HERTHENA-Lung01 and TROPION-Lung05 studies.

MARIPOSA-2: Amivantamab and Chemotherapy in EGFR-Mutant NSCLC in Second Line and Beyond

Benjamin P. Levy, MD;Solange Peters, MD, PhD;Joshua K. Sabari, MD;Edward B. Garon, MD, MS;Marina Chiara Garassino, MD

December 27th 2023

A panel of experts on non–small cell lung cancer provide their thoughts MARIPOSA-2, which studied amivantamab and chemotherapy in EGFR-mutant NSCLC in the second line and beyond.

Joshua K. Sabari, MD, and Marina Chiara Garassino, MD, experts on non-small cell lung cancer

Treatment Options in EGFR-Mutant NSCLC in Second Line and Beyond

Benjamin P. Levy, MD;Solange Peters, MD, PhD;Joshua K. Sabari, MD;Edward B. Garon, MD, MS;Marina Chiara Garassino, MD

December 20th 2023

Joshua K. Sabari, MD, reviews data from the MARIPOSA-2 trial and discusses treatment options in the second line and beyond for patients with EGFR-mutant non–small cell lung cancer.

MARIPOSA: Amivantamab and Lazertinib in Frontline EGFR-Mutant NSCLC

Benjamin P. Levy, MD;Solange Peters, MD, PhD;Joshua K. Sabari, MD;Edward B. Garon, MD, MS;Marina Chiara Garassino, MD

December 20th 2023

The panel reacts to the MARIPOSA trial, which looked at amivantamab and lazertinib in the front line in patients with EGFR-mutant non–small cell lung cancer.

FLAURA2: Osimertinib and Chemotherapy in Frontline EGFR-Mutant NSCLC

Benjamin P. Levy, MD;Solange Peters, MD, PhD;Joshua K. Sabari, MD;Edward B. Garon, MD, MS;Marina Chiara Garassino, MD

December 15th 2023

Comprehensive insights on FLAURA2, which looked at osimertinib and chemotherapy in the front line for patients with EGFR-mutant NSCLC.

First-Line Treatment for EGFR-Mutant Advanced Lung Cancer

Benjamin P. Levy, MD;Solange Peters, MD, PhD;Joshua K. Sabari, MD;Edward B. Garon, MD, MS;Marina Chiara Garassino, MD

December 15th 2023

A panel of thoracic medical oncologists discuss the first-line treatment options for patients with EGFR-mutant advanced non–small cell lung cancer.

A Role for Biomarkers in Selecting Appropriate Patients for ADCs in NSCLC

Benjamin P. Levy, MD;Solange Peters, MD, PhD;Joshua K. Sabari, MD;Edward B. Garon, MD, MS;Marina Chiara Garassino, MD

December 6th 2023

Expert perspectives on the role of clinical biomarkers in selecting appropriate patients for antibody-drug conjugates in non–small cell lung cancer.

TROPION-Lung04: Dato-DXd Plus Immunotherapy in Advanced NSCLC

Benjamin P. Levy, MD;Solange Peters, MD, PhD;Joshua K. Sabari, MD;Edward B. Garon, MD, MS;Marina Chiara Garassino, MD

December 6th 2023

Joshua K. Sabari, MD, reviews data from the TROPION-Lung04 study, and the panel offers key takeaways on Dato-DXd and immunotherapy in advanced NSCLC.

EVOKE-02: Sacituzumab Govitecan Plus Pembrolizumab in Advanced NSCLC

Benjamin P. Levy, MD;Solange Peters, MD, PhD;Joshua K. Sabari, MD;Edward B. Garon, MD, MS;Marina Chiara Garassino, MD

November 29th 2023

Edward B. Garon, MD, MS, reviews data from the EVOKE-02 study, and the panel offers their thoughts on antibody-drug conjugates for the treatment of advanced NSCLC.

Expert Perspectives on the Results of the TROPION-Lung01 Study in NSCLC

Benjamin P. Levy, MD;Solange Peters, MD, PhD;Joshua K. Sabari, MD;Edward B. Garon, MD, MS;Marina Chiara Garassino, MD

November 29th 2023

The expert panel reviews the results from the TROPION-Lung01 study and discusses how the data can inform treatment decisions for patients with previously treated NSCLC.

Two experts on lung cancer seated at a table

TROPION-Lung01: Dato-DXd in Previously Treated Advanced NSCLC

Benjamin P. Levy, MD;Solange Peters, MD, PhD;Joshua K. Sabari, MD;Edward B. Garon, MD, MS;Marina Chiara Garassino, MD

November 22nd 2023

Solange Peters, MD, PhD, reviews key data from TROPION-Lung01 investigating datopotamab deruxtecan (Dato-DXd) in patients with previously treated advanced non–small cell lung cancer.

NSCLC: PD-L1 Expression and Treatment Decision-Making

Benjamin P. Levy, MD;Solange Peters, MD, PhD;Joshua K. Sabari, MD;Edward B. Garon, MD, MS;Marina Chiara Garassino, MD

November 22nd 2023

Clinical insights on how the level of PD-L1 expression informs treatment decisions for patients with non–small cell lung cancer.

The Role of CTLA-4 Inhibitors in NSCLC

Benjamin P. Levy, MD;Solange Peters, MD, PhD;Joshua K. Sabari, MD;Edward B. Garon, MD, MS;Marina Chiara Garassino, MD

November 15th 2023

Experts on non–small cell lung cancer discuss the role of CTLA-4 inhibitors in the NSCLC treatment landscape.

First-Line Treatment Strategies for Advanced Non–Small Cell Lung Cancer

Benjamin P. Levy, MD;Solange Peters, MD, PhD;Joshua K. Sabari, MD;Edward B. Garon, MD, MS;Marina Chiara Garassino, MD

November 15th 2023

A panel of thoracic medical oncologists provide an overview of first-line treatment strategies for advanced non–small cell lung cancer (NSCLC).

Combination Chemotherapy and Immunotherapy for Advanced NSCLC

Jarushka Naidoo, MD, M.B.B.Ch.;Solange Peters, MD, PhD;Marina Chiara Garassino, MD

May 23rd 2023

Experts review data updates on chemotherapy / immunotherapy combination treatments in advanced NSCLC.

The Evolution of Chemoimmunotherapy in Advanced NSCLC

Jarushka Naidoo, MD, M.B.B.Ch.;Solange Peters, MD, PhD;Marina Chiara Garassino, MD

May 23rd 2023

Closing their discussion, the panel shares their final thoughts on recent updates in advanced NSCLC and looks to the future of treatment.

Updates from ELCC: 5-Year Update on Pembrolizumab vs Chemotherapy in Advanced NSCLC

Jarushka Naidoo, MD, M.B.B.Ch.;Solange Peters, MD, PhD;Marina Chiara Garassino, MD

May 16th 2023

Jarushka Naidoo, MD, M.B.B.Ch., explains the 5-year-data update from a study investigating single-agent pembrolizumab vs chemotherapy for advanced NSCLC.

Updates from ELCC: Advanced NSCLC and the EMPOWER-Lung1 Trial

Jarushka Naidoo, MD, M.B.B.Ch.;Solange Peters, MD, PhD;Marina Chiara Garassino, MD

May 16th 2023

The panel reviews data presented at ELCC from EMPOWERLung1 investigating cemiplimab versus chemotherapy in patients with advanced NSCLC.

Data Updates on Single-Agent Immunotherapy in Advanced NSCLC

Jarushka Naidoo, MD, M.B.B.Ch.;Solange Peters, MD, PhD;Marina Chiara Garassino, MD

May 9th 2023

Experts explain recent data updates on single-agent immunotherapy treatment for patient with advanced NSCLC.

Updates from ELCC: Efficacy of Frontline Nivolumab + Ipilimumab in Metastatic Non-Squamous NSCLC

Jarushka Naidoo, MD, M.B.B.Ch.;Solange Peters, MD, PhD;Marina Chiara Garassino, MD

May 9th 2023

Dr Solange Peters reviews data on the efficacy and toxicities of first-line nivolumab and ipilimumab for metastatic non-squamous NSCLC.

Updates in Gender-Based Treatment for Patients with Advanced NSCLC

Jarushka Naidoo, MD, M.B.B.Ch.;Solange Peters, MD, PhD;Marina Chiara Garassino, MD

May 2nd 2023

Jarushka Naidoo, MD, M.B.B.Ch., explains the debate on the gender differences in advanced NSCLC treatment.

CTLA-4 Targeted Regimens in Advanced NSCLC

Jarushka Naidoo, MD, M.B.B.Ch.;Solange Peters, MD, PhD;Marina Chiara Garassino, MD

April 26th 2023

Solange Peters, MD, PhD, detail the subgroups of patients with advanced NSCLC and how treatment varies.

Subgrouping Patients with Advanced NSCLC for Tailored Treatment

Jarushka Naidoo, MD, M.B.B.Ch.;Solange Peters, MD, PhD;Marina Chiara Garassino, MD

April 25th 2023

The panel discusses how patients with advanced NSCLC are sub-grouped in NSCLC and how to approach treatment for each group.

Overview of PD-L1 Testing in Advanced NSCLC

Jarushka Naidoo, MD, M.B.B.Ch.;Solange Peters, MD, PhD;Marina Chiara Garassino, MD

April 25th 2023

Marina Garassino, MD, reviews the role of PD-L1 testing in advanced non-small cell lung cancer.

Dr. Garassino on Updates From the KEYNOTE-189 Trial in NSCLC

Marina Chiara Garassino, MD

October 21st 2022

Marina Chiara Garassino, MD, discusses updates from the phase 3 KEYNOTE-189 trial in non–small cell lung cancer.

Dr. Garassino on the Clinical Implications of Tepotinib in METex14-Altered NSCLC

Marina Chiara Garassino, MD

September 24th 2021

Marina Chiara Garassino, MD, professor of Medicine, Hematology and Oncology, The University of Chicago Department of Medicine, discusses the clinical implications of the phase 2 VISION trial evaluating patients with MET exon 14 skipping mutation–positive non–small cell lung cancer.

Dr. Garassino on Subgroup Analyses of the VISION Trial in METex14-Altered NSCLC

Marina Chiara Garassino, MD

September 18th 2021

Marina Garassino, MD, discusses the results of subgroup analyses of the phase 2 VISION trial in MET exon 14 skipping mutation–positive non-small cell lung cancer.